免疫检查点抑制剂相关肉芽肿性炎症的淋巴结抽吸细胞学表现
本文报告了5例晚期黑色素瘤(III期)患者在接受免疫检查点抑制剂(如Ipilimumab和Nivolumab)治疗后,PET/CT显示新发淋巴结肿大疑似恶性,超声引导下细针穿刺(FNA)细胞学显示大量肉芽肿性炎症,排除真菌和分枝杆菌感染,诊断为免疫检查点抑制剂相关肉芽肿性炎症。停药并给予泼尼松后病情改善,淋巴结肿大消退。FNA可作为微创工具探查此类患者淋巴结肿大的原因。
要点
- 免疫检查点抑制剂治疗后可出现肉芽肿性炎症,表现为PET/CT新发淋巴结肿大疑似恶性。
- FNA细胞学显示大量肉芽肿,需排除感染,可确诊此罕见不良事件。
- 停药和泼尼松治疗可改善病情,淋巴结肿大消退。
核心结论
- 免疫检查点抑制剂(如Ipilimumab和Nivolumab)治疗相关肉芽肿性炎症是一种不良事件,可表现为PET/CT疑似恶性的淋巴结肿大。
- FNA可作为微创工具探查此类患者淋巴结肿大的原因。
研究设计与样本
- 病例系列,5例晚期黑色素瘤(III期)患者(4男1女),接受免疫检查点抑制剂治疗。
主要发现
- 5例患者均无自身免疫性疾病、AIDS或结节病病史,PET/CT显示新发淋巴结肿大疑似恶性。
- 4例为皮肤黑色素瘤,1例为阴道黑色素瘤;3例单药治疗(2例Nivolumab,1例Ipilimumab),2例双药治疗(Ipilimumab+Pembrolizumab或Ipilimumab+Nivolumab)。
- PET/CT显示4例纵隔多站淋巴结肿大,1例门脉周围淋巴结肿大。
- 超声引导下FNA显示大量肉芽肿性炎症,真菌和分枝杆菌感染被排除;细胞形态学上肉芽肿多、大、细胞丰富、无坏死,多核巨细胞罕见或未见,细胞块无纤维化。
- 其他不良事件包括口腔溃疡、流感样症状、关节炎、肌肉疼痛、皮疹、轻度和重度结肠炎;1例发生严重肾上腺功能不全。
临床怎么用
- 对于免疫检查点抑制剂治疗的患者,出现新发淋巴结肿大时,应考虑肉芽肿性炎症的可能,FNA可帮助鉴别诊断。
- 确诊后应停药并给予泼尼松治疗,需监测肾上腺功能不全等不良反应。
局限性
- 样本量小(5例),为病例系列,证据级别有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune checkpoint inhibitors are a major breakthrough in the field of oncology. Targets for approved immune checkpoint inhibitors are cytotoxic T-lymphocytes-associated antigen 4 (CTLA-4) and programmed cell death receptor 1/ programmed cell death ligand 1 (PD-1/PD-L1). Five patients (four males and one female) were treated with immune checkpoint inhibitors for advanced melanoma (stage III). None of them had prior history of autoimmune disorders, AIDS, or sarcoidosis. The PET/CT imaging studies showed new onset lymphadenopathy suspicious for malignancy. Four patients had cutaneous melanoma and one had vaginal melanoma. Three patients were treated with single agent (two Nivolumab, one Ipilimumab) and two with double agents (Ipilimumab and Pembrolizumab, or Ipilimumab and Nivolumab). PET/CT showed mediastinal multistational lymphadenopathy in four cases and peri-portal lymphadenopathy in one patient. Ultrasound-guided fine needle aspiration (FNA) biopsy showed numerous sarcoid-like granulomatous inflammation, while the fungal and mycobacterial infections were excluded. Cytomorphologically, the granulomas were numerous, mostly large, cellular and non-necrotizing. Multi-nucleated giant were rare or not seen at all. Cell blocks did not show any fibrosis. Other adverse effects included mouth sores, flu-like symptoms, arthritis, muscle aches, skin rashes, mild and severe colitis. The treatment was stopped and patients received prednisone. One patient developed severe adrenal insufficiency, which prolonged prednisone tapering. Their condition improved and lymphadenopathy was resolved in follow-up imaging. Sarcoid-like granulomatous inflammation is an adverse event in patients treated with immune checkpoint therapy such as Ipilimumab and Nivolumab. It can present as enlarged lymph nodes in PET/CT imaging suspicious for malignancy. FNA can serve as a minimally invasive tool to investigate the underlying cause of lymphadenopathy in this subset of patients.
引用
- Rodriguez EF, Lipson E, Suresh K, et al. Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma. Hum Pathol. 2019. PMID: 31279873. doi:10.1016/j.humpath.2019.07.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。